Login to Your Account



PharmaFocus

Study Confirms Zytiga's Benefit in Earlier-Stage Prostate Cancer

By Nuala Moran
Staff Writer

Friday, December 14, 2012
Scientists at the Institute of Cancer Research in London published Tuesday details of the Phase III trial of Johnson & Johnson's prostate cancer drug Zytiga (abiraterone acetate) in men who had not received chemotherapy, a day after the FDA agreed to a label extension allowing the drug to be used at that earlier stage of the disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription